NasdaqCM - Delayed Quote USD
Context Therapeutics Inc. (CNTX)
0.5880
+0.0109
+(1.89%)
At close: June 2 at 4:00:02 PM EDT
0.5982
+0.01
+(1.73%)
After hours: June 2 at 7:41:20 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director | 765.6k | -- | 1984 |
| Ms. Jennifer Minai-Azary | CFO & Treasurer | 564.09k | -- | 1978 |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary | 541.33k | -- | 1979 |
| Dr. Karen L. Smith L.L.M., M.B.A., M.D., PH.D. | Interim Chief Medical Officer & Director | 14.55k | -- | 1968 |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | -- | -- | -- |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
Context Therapeutics Inc.
2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Corporate Governance
Context Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 8:09 PM UTC
Context Therapeutics Inc. Earnings Date
Recent Events
Related Tickers
FBLG FibroBiologics, Inc.
0.7631
+4.61%
OVID Ovid Therapeutics Inc.
0.2899
+6.50%
CGTX Cognition Therapeutics, Inc.
0.3170
+32.64%
RLYB Rallybio Corporation
0.2862
-7.38%
INDP Indaptus Therapeutics, Inc.
0.3404
+0.71%
ENSC Ensysce Biosciences, Inc.
2.2200
0.00%
BOLD Boundless Bio, Inc.
1.1300
+2.73%
LGVN Longeveron Inc.
1.2500
+0.81%
CLYM Climb Bio, Inc.
1.1800
0.00%
ACRV Acrivon Therapeutics, Inc.
1.1100
+5.71%